Zimmer Biomet (NYSE:ZBH - Get Free Report) updated its FY 2024 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 8.000-8.150 for the period, compared to the consensus estimate of 8.060. The company issued revenue guidance of $7.7 billion-$7.8 billion, compared to the consensus revenue estimate of $7.8 billion.
Wall Street Analyst Weigh In
A number of equities research analysts have recently weighed in on the company. Royal Bank of Canada reaffirmed an outperform rating and issued a $140.00 price objective on shares of Zimmer Biomet in a research note on Friday, February 9th. Citigroup raised their price target on shares of Zimmer Biomet from $134.00 to $140.00 and gave the company a neutral rating in a research report on Wednesday, April 3rd. Needham & Company LLC reissued a hold rating on shares of Zimmer Biomet in a research note on Thursday. Truist Financial decreased their price objective on Zimmer Biomet from $137.00 to $130.00 and set a hold rating for the company in a research note on Friday. Finally, TheStreet upgraded shares of Zimmer Biomet from a c rating to a b- rating in a report on Thursday, February 8th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of Hold and a consensus target price of $139.00.
Get Our Latest Analysis on Zimmer Biomet
Zimmer Biomet Price Performance
NYSE:ZBH traded up $3.22 during trading hours on Friday, hitting $121.68. The company's stock had a trading volume of 1,847,585 shares, compared to its average volume of 1,482,554. The company has a market capitalization of $25.00 billion, a PE ratio of 24.88, a PEG ratio of 2.20 and a beta of 1.03. Zimmer Biomet has a 52-week low of $102.00 and a 52-week high of $147.50. The business's 50-day moving average is $125.45 and its two-hundred day moving average is $119.90. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.78 and a current ratio of 1.61.
Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.94 EPS for the quarter, beating the consensus estimate of $1.87 by $0.07. Zimmer Biomet had a net margin of 13.85% and a return on equity of 12.79%. The firm had revenue of $1.89 billion during the quarter, compared to analysts' expectations of $1.87 billion. During the same quarter last year, the business earned $1.89 earnings per share. The business's revenue for the quarter was up 3.2% compared to the same quarter last year. As a group, research analysts anticipate that Zimmer Biomet will post 8.08 EPS for the current fiscal year.
Zimmer Biomet Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th were given a dividend of $0.24 per share. The ex-dividend date was Wednesday, March 27th. This represents a $0.96 dividend on an annualized basis and a yield of 0.79%. Zimmer Biomet's payout ratio is 19.63%.
Insider Activity
In related news, VP Chad F. Phipps sold 26,156 shares of the stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total value of $3,364,184.72. Following the sale, the vice president now directly owns 44,145 shares of the company's stock, valued at approximately $5,677,929.90. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 0.95% of the company's stock.
Zimmer Biomet Company Profile
(
Get Free Report)
Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.
See Also
Before you consider Zimmer Biomet, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zimmer Biomet wasn't on the list.
While Zimmer Biomet currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
